Gabaergic and glutamatergic modulation in binge eating: Therapeutic approach

Current Pharmaceutical Design

Volumn 17, Issue 14, 2011, Pages 1396-1409

  Guardia, Dewi ^a,b   Rolland, Benjamin ^b   Karila, Laurent ^c   Cottencin, Olivier ^a,b  

^a UNIV LILLE   (France)

^b CHULille   (France)

^c HÔPITAL PAUL BROUSSE   (France)

Author keywords

Baclofen; Binge eating; Eating disorders; Gaba; Glutamate; Topiramate

Indexed keywords

4 AMINOBUTYRIC ACID; ACAMPROSATE; ALCOHOL; BACLOFEN; CYTOCHROME P450 3A4; GABAPENTIN; LAMOTRIGINE; METHYLPHENIDATE; SERTRALINE; TIAGABINE; TOPIRAMATE; VENLAFAXINE;

ACNE; ALCOHOLISM; ATTENTION DISTURBANCE; BACKACHE; BINGE EATING DISORDER; BINGE EATING SCALE; BULIMIA; CLINICAL GLOBAL IMPRESSION SCALE; CONFUSION; CONSTIPATION; DEPRESSION; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DIARRHEA; DIZZINESS; DRUG ABSORPTION; DRUG ACTIVITY; DRUG EFFECT; DRUG ELIMINATION; DRUG ERUPTION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DYSPEPSIA; DYSURIA; EDEMA; FATIGUE; GABAERGIC SYSTEM; GABAERGIC TRANSMISSION; GLUTAMATERGIC NEUROTRANSMISSION; HALLUCINATION; HUMAN; HYPESTHESIA; HYPOTENSION; INSOMNIA; IRRITABILITY; LANGUAGE DISABILITY; LEG PAIN; MALAISE; MEDLINE; MEMORY DISORDER; MUSCLE WEAKNESS; NAUSEA; NERVOUSNESS; NEUROMODULATION; NEUROTRANSMISSION; OBESITY; PARANOIA; PARESTHESIA; POLYURIA; PRIORITY JOURNAL; PSYCHOMOTOR DISORDER; QUALITY OF LIFE; RATING SCALE; REVIEW; SIDE EFFECT; SOMNOLENCE; TASTE DISORDER; TOOTH PAIN; TREMOR; UPPER RESPIRATORY TRACT INFECTION; VISUAL IMPAIRMENT; WITHDRAWAL SYNDROME; XEROSTOMIA;

ANIMALS; BINGE-EATING DISORDER; BULIMIA NERVOSA; DRUG DELIVERY SYSTEMS; EATING DISORDERS; FEMALE; GAMMA-AMINOBUTYRIC ACID; GLUTAMIC ACID; HUMANS; MALE; REWARD;

EID: 79959939594     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/138161211796150828     Document Type: Review

References (130)

1. Hudson JI, Hiripi E, Pope HG Jr, Kessler RC. The prevalence and correlates of eating disorders in the National Comorbidity Survey replication. Biol Psychiatry 2007; 61: 348-58
2. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th ed., Text Revision. Washington, DC: American Psychiatric Association, 2000.
3. Striegel-Moore RH, Cachelin FM, Dohm FA, Pike KM, Wilfley DE, Fairburn CG. Comparison of binge eating disorder and bulimia nervosa in a community sample. Int J Eat Disord 2001; 29: 157-65
4. Grucza RA, Przybeck TR, Cloninger CR. Prevalence and correlates of binge eating disorder in a community sample. Compr Psychiatry 2007; 48: 124-31
5. Howell MJ, Schenck CH, Crow SJ. A review of nighttime eating disorders. Sleep Med Rev. 2009; 13: 23-34. Review.
6. Allison KC, Lundgren JD, O'Reardon JP, Geliebter A, Gluck ME, Vinai P, et al. Proposed diagnostic criteria for night eating syndrome. Int J Eat Disord. 2010; 43: 241-7
7. Striegel-Moore RH, Dohm FA, Hook JM, Schreiber GB, Crawford PB, Daniels SR. Night eating syndrome in young adult women: prevalence and correlates. Int J Eat Disord. 2005; 37: 200-6.
8. Lamerz A, Kuepper-Nybelen J, Bruning N, et al. Prevalence of obesity, binge eating, and night eating in a cross-sectional field survey of 6-year-old children and their parents in a German urban population. J Child Psychol Psychiatry 2005; 46: 385-93.
9. Winkelman JW, Herzog DB, Fava M. The prevalence of sleeprelated eating disorder in psychiatric and nonpsychiatric populations. Psychol Med 1999; 29: 1461-6.
10. NICE. Eating disorders-core interventions in the treatment and management of anorexia nervosa, bulimia nervosa and related eating disorders. NICE Clinical Guideline no 9. London: NICE, 2004: http://www.nice.org.uk
11. Wilson GT, Shafran R. Eating disorders guidelines from NICE. Lancet. 2005; 365: 79-81.
12. Yager J. Binge eating disorder: the search for better treatments. Am J Psychiatry. 2008; 165(1): 4-6.
13. Appolinario JC, Bacaltchuk J, Sichieri R, et al. A randomized, doubleblind, placebo-controlled study of sibutramine in the treatment of binge-eating disorder. Arch Gen Psychiatry 2003; 60:1109-16.
14. Wilfley DE, Crow SJ, Hudson JI, et al. Efficacy of sibutramine for the treatment of binge eating disorder: a randomized multicenter placebocontrolled double-blind study. Am J Psychiatry 2008; 165:51-8.
15. McElroy SL, Kotwal R, Guerdjikova A, et al. Zonisamide in the treatment of binge eating disorder with obesity: a placebocontrolled trial. J Clin Psychiatry 2006; 67: 1897-906.
16. McElroy SL, Guerdjikova A, Kotwal R, et al. Atomoxetine in the treatment of binge-eating disorder: a randomized placebocontrolled trial. J Clin Psychiatry 2007; 68: 390-8.
17. O'Reardon JP, Stunkard AJ, Allison KC. Clinical trial of sertraline in the treatment of night eating syndrome. Int J Eat Disord 2004;35: 16-26.
18. O'Reardon JP, Allison KC, Martino NS, Lundgren JD, Heo M, Stunkard AJ. A randomized, placebo-controlled trial of sertraline in the treatment of night eating syndrome. Am J Psychiatry 2006; 163: 893-8.
19. Schenck CH, Hurwitz TD, Bundlie SR, Mahowald MW. Sleep related eating disorders: polysomnographic correlates of a heterogeneous syndrome distinct from daytime eating disorders. Sleep 1991; 14: 419-31.
20. Cruz HG, Ivanova T, Lunn ML, Stoffel M, Slesinger PA, Lüscher C. Bidirectional effects of GABA(B) receptor agonists on the mesolimbic dopamine system. Nat Neurosci 2004; 7: 153-159.
21. Rawlins PK. Intrathecal baclofen therapy over 10 years. J Neurosci Nurs 2004; 36: 322-327.
22. Johnson BA, Ait-Daoud N. Topiramate in the new generation of drugs: efficacy in the treatment of alcoholic patients. Curr Pharm Des 2010; 16: 2103-12. Review.
23. Tyacke RJ, Lingford-Hughes A, Reed LJ, Nutt DJ. GABAB receptors in addiction and its treatment. Adv Pharmacol 2010; 58: 373-96.
24. Rolland B, Deheul S, Danel T, Bordet R, Cottencin O. A System of Prescriptions without Drug Approval: Example of Baclofen. Therapie 2010; 65: 511-518.
25. Fink-Jensen A, Suzdak PD, Swedberg MD, Judge ME, Hansen L, Nielsen PG. The gamma-aminobutyric acid (GABA) uptake inhibitor, tiagabine, increases extracellular brain levels of GABA in awake rats. Eur J Pharmacol 1992; 220: 197-201.
26. Kalviainen R. Long-term safety of tiagabine. Epilepsia 2001; 42: 46-8.
27. Genton P, Guerrini R, Perucca E. Tiagabine in clinical practice. Epilepsia 2001; 42: 42-5. Review
28. Leppik E. Tiagabine: the safety landscape. Epilepsia 1995; 36: 10- 3.
29. Leppik IE, Gram L, Deaton R, Sommerville KW. Safety of tiagabine: summary of 53 trials. Epilepsy Res 1999; 33: 235-46.
30. Cuadrado A, de las Cuevas I, Valdizán EM, Armijo JA. Synergistic interaction between valproate and lamotrigine against seizures induced by 4-aminopyridine and pentylenetetrazole in mice. Eur J Pharmacol 2002; 453(1): 43-52.
31. Nielsen JN, Licht RW, Fogh K. Two cases of acneiform eruption associated with lamotrigine. J Clin Psychiatry 2004; 65: 1720-2.
32. Licht RW, Nielsen JN, Gram LF, Vestergaard P, Bendz H. Lamotrigine versus lithium as maintenance treatment in bipolar I disorder: an open, randomized effectiveness study mimicking clinical practice. The 6th trial of the Danish University Antidepressant Group (DUAG-6). Bipolar Disord 2010; 12: 483-93.
33. Mason BJ, Goodman AM, Dixon RM, et al. A pharmacokinetic and pharmacodynamic drug interaction study of acamprosate and naltrexone. Neuropsychopharmacology 2002; 27: 596-606.
34. Agelink MW, Lemmer W, Malessa R, Zeit T, Majewski T, Klieser E. Improved autonomic neurocardial balance in short-term abstinent alcoholics treated with acamprosate. Alcohol Alcohol 1998; 33: 602-5.
35. Richard D, Ferland J, Lalonde J, Samson P, Deshaies Y. Influence of topiramate in the regulation of energy balance. Nutrition 2000; 16: 961-6.
36. Cassin SE, von Ranson KM. Is binge eating experienced as an addiction? Appetite. 2007; 49: 687-90.
37. Avena NM. The study of food addiction using animal models of binge eating. Appetite. 2010; 55: 734-7.
38. Broft AI, Spanos A, Corwin RL, et al. Baclofen for binge eating: an open-label trial. Int J Eat Disord. 2007; 40: 687-91.
39. Johnson JG, Spitzer RL, Williams JB. Diagnostic and Statistical Manual of Mental Disorders - IV TR. Washington, DC: American Psychiatric Association, 2000.
40. Sinha R, O'Malley SS. Alcohol and eating disorders: implications for alcohol treatment and health services research. Alcohol Clin Exp Res 2000; 24: 1312-1319.
41. Herzog DB, Franko DL, Dorer DJ, Keel PK, Jackson S, Manzo MP. Drug abuse in women with eating disorders. Int J Eat Disord. 2006; 39: 364-8.
42. Bulik CM, Klump KL, Thornton L, et al. Alcohol use disorder comorbidity in eating disorders: a multicenter study. J Clin Psychiatry 2004; 65: 1000-6.
43. Pierce RC, Kumaresan V. The mesolimbic dopamine system: the final common pathway for the reinforcing effect of drugs of abuse? Neurosci Biobehav Rev 2006; 30: 215-38.
44. Noble F. Current preclinical knowledge of the neurobiology of cocaine. Presse Med. 2008; 37: 1767-72.
45. Schmidt HD, Pierce RC. Cocaine-induced neuroadaptations in glutamate transmission: potential therapeutic targets for craving and addiction. Ann N Y Acad Sci. 2010; 1187: 35-75. Review.
46. Uher R, Murphy T, Brammer MJ, et al. Medial prefrontal cortex activity associated with symptom provocation in eating disorders. Am J Psychiatry. 2004; 161: 1238-46.
47. Kenny PJ, Markou A. The ups and downs of addiction: role of metabotropic glutamate receptors. Trends Pharmacol Sci 2004; 25: 265-72.
48. Addolorato G, Caputo F, Capristo E, Colombo G, Gessa GL, Gasbarrini G. Ability of baclofen in reducing alcohol craving and intake: II--Preliminary clinical evidence. Alcohol Clin Exp Res 2000; 24: 67-71.
49. Flannery, BA, Garbutt, JC, Cody, et al. Baclofen for alcohol dependence: A preliminary open-label study. Alcohol Clin Exp Res 2004; 28(10), 1517-23.
50. Addolorato G, Leggio L, Ferrulli A, et al. Effectiveness and safety of baclofen for maintenance of alcohol abstinence in alcoholdependent patients with liver cirrhosis: Randomised, double-blind controlled study. Lancet 2007; 370: 1915-22.
51. Malcolm R, Myrick H, Brady KT, Ballenger JC. Update on anticonvulsants for the treatment of alcohol withdrawal. Am J Addict 2001; 9: 16-23.
52. Shoptaw S, Yang X, Rotheram-Fuller E J, et al. Randomized placebo- controlled trial of baclofen for cocaine dependence: Preliminary effects for individuals with chronic patterns of cocaine use. J Clin Psychiatry 2003; 64: 1440-8.
53. Kahn R, Biswas K, Childress AR, et al. Multi-center trial of baclofen for abstinenceinitiationinseverecocaine-dependentindividuals. Drug Alcohol Depend 2009; 103: 59-64.
54. Brebner K, Childress AR, Roberts DC. A potential role for GABA(B) agonists in the treatment of psychostimulant addiction. Alcohol Alcohol 2002; 37: 478-84.
55. Filip M, Frankowska M, Zaniewska M, Gołda A, Przegaliński E, Vetulani J. Diverse effects of GABA-mimetic drugs on cocaineevoked self-administration and discriminative stimulus effects in rats. Psychopharmacology 2007; 192(1): 17-26.
56. Brodie JD, Case BG, Figueroa E, et al. Randomized, double-blind, placebo-controlled trial of vigabatrin for the treatment of cocaine dependence in Mexican parolees. Am J Psychiatry 2009; 166: 1269-77.
57. Gonzalez G, Sevarino K, Sofuoglu M, et al. Tiagabine increases cocaine-free urines in cocaine-dependent methadone-treated patients: results of a randomized pilot study. Addiction. 2003; 98(11): 1625-32.
58. Winhusen TM, Somoza EC, Harrer JM, et al. A placebo-controlled screening trial of tiagabine, sertraline and donepezil as cocaine dependence treatments. Addiction 2005; 100; 68-77.
59. González G, Desai R, Sofuoglu M, et al. Clinical efficacy of gabapentin versus tiagabine for reducing cocaine use among cocaine ependent methadone-treated patients. Drug Alcohol Depend 2007; 87: 1-9.
60. Winhusen T, Somoza E, Ciraulo DA, et al. A double-blind, placebo- ontrolled trial of tiagabine for the treatment of cocaine dependence. Drug Alcohol Depend 2007; 91: 141-8.
61. Assadi SM, Radgoodarzi R, Ahmadi-Abhari SA. Baclofen for aintenance treatment of opioid dependence: a randomized double- lind placebo-controlled clinical trial. BMC Psychiatry 2003; 3: 6.
62. Spano MS, Fattore L, Fratta W, Fadda P. The GABAB receptor gonist baclofen prevents heroin-induced reinstatement of heroinseeking ehavior in rats. Neuropharmacology 2007; 52: 1555-62.
63. White WD, Crockford D, Patten S, El-Guebaly N. A randomized, pen-label pilot comparison of gabapentin and bupropion SR for smoking cessation. Nicotine Tob Res 2005; 7: 809-13.
64. Franklin TR, Harper D, Kampman K, et al. The GABA B agonist baclofen reduces cigarette consumption in a preliminary doubleblind placebo-controlled smoking reduction study. Drug Alcohol Depend. 2009; 103: 30-6.
65. Bisaga A, Comer SD, Ward AS, Popik P, Kleber HD, Fischman MW. The NMDA antagonist memantine attenuates the expression of opioid physical dependence in humans. Psychopharmacology 2001; 157: 1-10.
66. Van den Pol AN. Weighing the role of hypothalamic feeding neurotransmitters. Neuron 2003; 40: 1059-61. Review.
67. Meister B. Neurotransmitters in key neurons of the hypothalamus that regulate feeding behavior and body weight. Physiol Behav 2007; 92: 263-71. Review.
68. Da Silva AA, Campanella LC, Ramos MC, Faria MS, Paschoalini MA, Marino-Neto J. Ingestive effects of NMDA and AMPAkainate receptor antagonists microinjections into the lateral hypothalamus of the pigeon (Columba livia). Brain Res. 2006; 1115: 75-82.
69. Stratford TR, Kelley AE. GABA in the nucleus accumbens shell participates in the central regulation of feeding behavior. J Neurosci 1997; 17: 4434-40.
70. Ebenezer IS, Baldwin BA. Effect of intracerebroventricular administration of the GABAB-receptor agonist baclofen on operant feeding in satiated pigs. Br J Pharmacol. 1990; 101: 559-62.
71. Stanley BG, Willett III VL, Donias HW, Ha LH, Spears LC. The lateral hypothalamus: a primary site mediating excitatory amino acid-elicited eating. Brain Res 1993; 630: 41-9.
72. Godart N, Berthoz S, Perdereau F, Jeammet P. Comorbidity of anxiety with eating disorders and OCD. Am J Psychiatry 2006; 163: 326-9.
73. Brietzke E, Moreira CL, Toniolo RA, Lafer B. Clinical correlates of eating disorder comorbidity in women with bipolar disorder type I. J Affect Disord 2010. [Epub ahead of print]
74. McElroy SL, Kotwal R, Keck PE Jr, Akiskal HS. Comorbidity of bipolar and eating disorders: distinct or related disorders with shared dysregulations? J Affect Disord 2005; 86: 107-27. Review.
75. Tagay S, Schlegl S, Senf W. Traumatic events, posttraumatic stress symptomatology and somatoform symptoms in eating disorder patients. Eur Eat Disord Rev 2010; 18: 124-32.
76. Arnone D. Review of the use of Topiramate for treatment of psychiatric disorders. Ann Gen Psychiatry 2005; 4: 5.
77. McElroy SL, Arnold LM, Shapira NA, et al. Topiramate in the treatment of binge eating disorder associated with obesity: a randomized, placebo-controlled trial. Am J Psychiatry 2003; 160: 255-61.
78. Claudino AM, Oliveira IR, Appolinario JC, et al. Double-blind, randomized, placebo-controlled trial of topiramate plus cognitivebehaviour therapy in binge-eating disorder. J Clin Psychiatry 2007; 68: 1324-32.
79. McElroy SL, Hudson JI, Capece JA, et al. Topiramate for the treatment of binge eating disorder associated with obesity: a placebo- controlled study. Biol Psychiatry 2007; 61: 1039-48.
80. Brambilla F, Samek L, Company M, Lovo F, Cioni L, Mellado C. Multivariate therapeutic approach to binge-eating disorder: combined nutritional, psychological and pharmacological treatment. Int Clin Psychopharmacol 2009; 24: 312-7.
81. Hoopes SP, Reimherr FW, Hedges DW, et al. Treatment of bulimia nervosa with topiramate in a randomized, double-blind, placebocontrolled trial, part 1: improvement in binge and purge measures. J Clin Psychiatry 2003; 64: 1335-41.
82. Nickel C, Tritt K, Muehlbacher M, et al. Topiramate treatment in bulimia nervosa patients: a randomized, double-blind, placebocontrolled trial. Int J Eat Disord 2005; 38: 295-300.
83. Guerdjikova AI, McElroy SL, Welge JA, Nelson E, Keck PE, Hudson JI. Lamotrigine in the treatment of binge-eating disorder with obesity: a randomized, placebo-controlled monotherapy trial. Int Clin Psychopharmacol 2009; 24: 150-8.
84. McElroy SL, Guerdjikova AI, Winstanley EL, et al. Acamprosate in the treatment of binge eating disorder: a placebo-controlled trial. Int J Eat Disord 2011; 44: 81-90.
85. Appolinario JC, Fontenelle LF, Papelbaum M, Bueno JR, Coutinho W. Topiramate use in obese patients with binge eating disorder: an open study. Can J Psychiatry 2002; 47: 271-273.
86. McElroy SL, Shapira NA, Arnold LM, et al. Topiramate in the long-term treatment of binge-eating disorder associated with obesity. J Clin Psychiatry 2004; 65: 1463-9.
87. Shapira NA, Goldsmith TD, McElroy S. Treatment of binge disorder with topiramate: a clinical case series. J Clin Psychiatry 2000; 61: 368-72.
88. Appolinario JC, Coutinh W, Fontenelle L. Topiramate for bingeeating disorder. Am J Psychiatry 2001; 158: 967-8.
89. Schmidt do Prado-Lima PA, Bacaltchuck J. Topiramate in treatment resistant depression and binge-eating disorder. Bipolar Disord 2002; 4: 271-3.
90. Zilberstein B, Pajecki D, Garcia de Brito AC, Gallafrio ST, Eshkenazy R, Andrade CG. Topiramate after adjustable gastric banding in patients with binge eating and difficulty losing weight. Obes Surg 2004; 14: 802-5.
91. Guerdjikova AI, Kotwal R, McElroy SL. Response of recurrent binge eating and weight gain to topiramate in patients with binge eating disorder after bariatric surgery. Obes Surg 2005; 15: 273-7. GABAergic and Glutamatergic Neurotransmission in Eating Disorders Current Pharmaceutical Design, 2011, Vol. 17, No. 14 1409
92. De Bernardi C, Ferraris S, D'Innella P, Do F, Torre E. Topiramate for binge eating disorder. Prog Neuropsychopharmacol Biol Psychiatry 2005; 29: 339-41.
93. Knable M. Topiramate for bulimia nervosa in epilepsy. Am J Psychiatry 2001; 158: 322-3.
94. Felstrom A, Blackshaw S. Topiramate for bulimia nervosa with bipolar II disorder. Am J Psychiatry 2002; 159: 1246-1247
95. Barbee JG. Topiramate in the treatment of severe bulimia nervosa with co-morbid mood disorders: a case series. Int J Eat Disord 2003; 33: 468-72.
96. Chiu YH, Lee TH, Shen WW. Use of low-dose topiramate in substance use disorder and body weight control. Psychiatry Clin Neurosci 2007; 61: 630-3.
97. Winkelman JW. Treatment of nocturnal eating syndrome and sleep-related eating disorder with topiramate. Sleep Med 2003; 4: 243-6.
98. Winkelman JW. Efficacy and tolerability of topiramate in the treatment of sleep related eating disorders: an open-label, retrospective case series. J Clin Psychiatry 2006; 67: 1729-34.
99. Martinez-Salio A, Soler-Algarra S, Calvo-Garcia I, Sanchez-Martin M. Nocturnal sleep-related eating disorder that responds to topiramate. Rev Neurol 2007; 45: 276-9.
100. Buda-Levin A, Wojnicki FH, Corwin RL. Baclofen reduces fat intake under binge-type conditions. Physiol Behav 2005; 86: 176-84.
101. Foltin RW. Baclofen decreases feeding in non-human primates. Pharmacol Biochem Behav 2005; 82: 608-14.
102. Han DH, Lyool IK, Sung YH, Lee SH, Renshaw PF. The effect of acamprosate on alcohol and food craving in patients with alcohol dependence. Drug Alcohol Depend. 2008; 93: 279-83.
103. Schenck CH, Connoy DA, Castellanos M, et al. Zolpidem-induced sleep-related eating disorder (SRED) in 19 patients. Sleep 2005; 28: A259.
104. Morgenthaler TI, Silber MH. Amnestic sleep-related eating disorder associated with zolpidem. Sleep Med 2002; 3: 323-7.
105. Wing YK, Lam SP, Li SX, Zhang J, Yu MW. Sleep-related eating disorder and zolpidem: an open interventional cohort study. J Clin Psychiatry 2010; 71: 653-6.
106. Schenck CH, Mahowald MW. Review of nocturnal sleeprelated eating disorders. Int J Eat Disord 1994; 15: 343-56.
107. Provini F, Albani F, Vertrugno R, et al. A pilot double-blind placebo controlled trial of low dose pramipexole in sleep related eating disorder. Eur J Neurol 2005; 12: 432-6.
108. Schenck CH, Mahowald MW. Topiramate therapy of sleep related eating disorder (SRED). Sleep 2006; 29: A268.
109. Marcotte D. Use of topiramate, a new anti-epileptic as a mood stabilizer. J Affect Disord 1998; 50: 245-51.
110. Grunze HC, Normann C, Langosch J, et al. Antimanic efficacy of topiramate in 11 patients in an open trial with an on-off-on design. J Clin Psychiatry 2001; 62: 464-8.
111. Carpenter LL, Leon Z, Yasmin S, Price LH. Do obese depressed patients respond to topiramate? A retrospective chart review. J Affect Disord 2002; 69: 251-5.
112. Biton V, Montouris GD, Ritter F, et al. A randomized, placebocontrolled study of topiramate in primary generalized tonic-clonic seizures. Topiramate YTC Study Group. Neurology 1999; 52:1330-7.
113. Biton V. Effect of antiepileptic drugs on bodyweight: overview and clinical implications for the treatment of epilepsy. CNS Drugs 2003; 17: 781-91. Review.
114. Reas DL, Grilo CM. Review and meta-analysis of pharmacotherapy for binge-eating disorder. Obesity 2008; 16: 2024-38.
115. Guille C, Sachs G. Clinical outcome of adjunctive topiramate treatment in a sample of refractory bipolar patients with comorbid conditions. Prog Neuropsychopharmacol Biol Psychiatry 2002; 26: 1035-9.
116. Rosenow F, Knake S, Hebebrand J. Topiramate and anorexia nervosa. Am J Psychiatry 2002; 159: 2112-3.
117. Colom F, Vieta E, Benabarre A, Martínez-Arán A, Reinares M, Corbella B, Gastó C. Topiramate abuse in a bipolar patient with an eating disorder. J Clin Psychiatry 2001; 62: 475-6.
118. Chung AM, Reed MD. Intentional topiramate ingestion in an adolescent female. Ann Pharmacother 2004; 38: 1439-42.
119. Ebenezer IS, Baldwin BA. Effect of intracerebroventricular administration of the GABAB-receptor agonist baclofen on operant feeding in satiated pigs. Br J Pharmacol 1990; 101: 559-62.
120. Hudson JI, McElroy SL, Raymond NC, et al. Fluvoxamine in the treatment of binge-eating disorder: a multicenter placebocontrolled, double-blind trial. Am J Psychiatry 1998; 155: 1756-62.
121. McElroy SL, Casuto LS, Nelson EB, Lake KA, Soutullo CA, Keck PE Jr, et al. Placebo-controlled trial of sertraline in the treatment of binge eating disorder. Am J Psychiatry 2000; 157: 1004-6
122. Arnold LA, McElroy SL, Hudson JI, Welge JA, Bennet AJ, Keck PE Jr. A placebo-controlled trial of fluoxetine in the treatment of binge eating disorder. J Clin Psychiatry 2002; 63: 1028-33.
123. Leombruni P, Pierò A, Lavagnino L, Brustolin A, Campisi S, Fassino S. A randomized, double-blind trial comparing sertraline and fluoxetine 6-month treatment in obese patients with Binge Eating Disorder. Prog Neuropsychopharmacol Biol Psychiatry 2008; 32: 1599-605.
124. Capasso A, Petrella C, Milano W. Pharmacological profile of SSRIs and SNRIs in the treatment of eating disorders. Curr Clin Pharmacol 2009; 4: 78-83.
125. Leombruni P, Lavagnino L, Gastaldi F, Vasile A, Fassino S. Duloxetine in obese binge eater outpatients: preliminary results from a 12-week open trial. Hum Psychopharmacol 2009; 24: 483-8.
126. McCann UD, Agras WS. Successful treatment of nonpurging bulimia nervosa with desipramine: a double blind, placebo-controlled study. Am J Psychiatry 1990; 147: 1509-13.
127. Laederach-Hofmann K, Graf C, Horber F, et al. Imipramine and diet counseling with psychological support in the treatment of obese binge eaters: a randomized, placebo-controlled double-blind study. Int J Eat Disord 1999; 26: 231-44.
128. Bacaltchuk J, Hay P. Antidepressants versus placebo for people with bulimia nervosa. In: The Cochrane Library Issue 2, 2007. Chichester, UK: John Wiley & Sons, Ltd. Search date 2003.
129. Wilfley DE, Welch R, Stein RI, et al. A randomized comparison of group cognitive-behavioral therapy and group interpersonal psychotherapy for the treatment of overweight individuals with bingeeating disorder. Arch Gen Psychiatry 2002; 59: 713-21.
130. Hay PJ, Bacaltchuk J. Bulimia nervosa. Clin Evid (Online). 2008; 2008. pii: 1009.